These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 29555570

  • 1. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi JI.
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, Cho SB, Jeong YY.
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [Abstract] [Full Text] [Related]

  • 6. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA, Zeile M, Stavrou GA, Wacker F, Brüning R, Oldhafer KJ, Rodt T.
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [Abstract] [Full Text] [Related]

  • 7. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, Ou MC.
    BMC Gastroenterol; 2018 Aug 03; 18(1):124. PubMed ID: 30075752
    [Abstract] [Full Text] [Related]

  • 8. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H, Wu F, Duan M, Zhang G.
    Medicine (Baltimore); 2019 May 03; 98(21):e15314. PubMed ID: 31124925
    [Abstract] [Full Text] [Related]

  • 9. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
    Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y, Japan Interventional Radiology in Oncology Study Group-JIVROSG.
    Ups J Med Sci; 2013 Mar 03; 118(1):16-22. PubMed ID: 23167460
    [Abstract] [Full Text] [Related]

  • 10. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M.
    World J Gastroenterol; 2017 May 28; 23(20):3690-3701. PubMed ID: 28611522
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
    Adel H, Shazlee MK, Qamar S, Hyder SMS, Razaque A.
    Cureus; 2023 Jul 28; 15(7):e41701. PubMed ID: 37575777
    [Abstract] [Full Text] [Related]

  • 12. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.
    Cardiovasc Intervent Radiol; 2018 Mar 28; 41(3):433-442. PubMed ID: 29086058
    [Abstract] [Full Text] [Related]

  • 13. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS, Li HZ, Ma C, Xiao YD.
    BMC Cancer; 2019 Nov 29; 19(1):1162. PubMed ID: 31783814
    [Abstract] [Full Text] [Related]

  • 14. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B, Zhou J, Ling G, Zhu D, Long Q.
    World J Surg Oncol; 2018 Mar 27; 16(1):69. PubMed ID: 29587773
    [Abstract] [Full Text] [Related]

  • 15. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB.
    BMC Cancer; 2015 Jun 10; 15():465. PubMed ID: 26059447
    [Abstract] [Full Text] [Related]

  • 16. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.
    Schindler P, Kaldewey D, Rennebaum F, Trebicka J, Pascher A, Wildgruber M, Köhler M, Masthoff M.
    J Cancer Res Clin Oncol; 2024 May 06; 150(5):235. PubMed ID: 38710956
    [Abstract] [Full Text] [Related]

  • 17. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS.
    Ann Oncol; 2013 Apr 06; 24(4):965-73. PubMed ID: 23223331
    [Abstract] [Full Text] [Related]

  • 18. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J, Wang N, Shi C, Liu Q, Song J, Ye X.
    J Cancer Res Ther; 2021 Jul 06; 17(3):733-739. PubMed ID: 34269307
    [Abstract] [Full Text] [Related]

  • 19. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
    Rahman FA, Naidu J, Ngiu CS, Yaakob Y, Mohamed Z, Othman H, Jarmin R, Elias MH, Hamid NA, Mokhtar NM, Ali RR.
    Asian Pac J Cancer Prev; 2016 Jul 06; 17(8):4037-41. PubMed ID: 27644658
    [Abstract] [Full Text] [Related]

  • 20. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, Zhao C, Xiang H, Zhao H, Zheng C, Xiong B, Li H, Long Q, Zhou J, Luo C, Hu H.
    Clin Res Hepatol Gastroenterol; 2021 Mar 06; 45(2):101460. PubMed ID: 32593695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.